VIATRIS INC. Increase (Decrease) in Accounts Receivable
VIATRIS INC. (VTRS) reported Increase (Decrease) in Accounts Receivable of $252.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- VIATRIS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $126.50M, a 1217.71% increase year-over-year.
- VIATRIS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $126.30M.
- VIATRIS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$271.90M.
- VIATRIS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $95.70M, a 190.00% increase year-over-year.
- VIATRIS INC. increase (decrease) in accounts receivable for fiscal 2025 was -$334.60M.
- VIATRIS INC. increase (decrease) in accounts receivable for fiscal 2024 was -$300.10M.
- VIATRIS INC. increase (decrease) in accounts receivable for fiscal 2023 was -$78.60M, a 132.71% decline from fiscal 2022.
- VIATRIS INC. increase (decrease) in accounts receivable for fiscal 2022 was $240.30M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $126.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $252.80M 10-Q · filed 2026-08-06 | -$19.10M derived: sum of 3 quarters · filed 2026-08-06 | $76.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $126.30M 10-Q · filed 2026-05-07 | -$145.60M derived: sum of 2 quarters · filed 2026-05-07 | -$49.90M derived: sum of 3 quarters · filed 2026-05-07 | -$40.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$271.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$176.20M derived: sum of 2 quarters · filed 2026-02-26 | -$166.60M derived: sum of 3 quarters · filed 2026-08-06 | -$334.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $95.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $105.30M derived: sum of 2 quarters · filed 2026-08-06 | -$62.70M 10-Q · filed 2025-11-06 | -$363.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $9.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$158.40M 10-Q · filed 2026-08-06 | -$458.90M derived: sum of 3 quarters · filed 2026-08-06 | -$425.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$168.00M 10-Q · filed 2026-05-07 | -$468.50M derived: sum of 2 quarters · filed 2026-05-07 | -$435.50M derived: sum of 3 quarters · filed 2026-05-07 | -$458.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$300.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$267.50M derived: sum of 2 quarters · filed 2026-02-26 | -$290.30M derived: sum of 3 quarters · filed 2026-02-26 | -$300.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $33.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.20M derived: sum of 2 quarters · filed 2025-11-06 | $400.00K 10-Q · filed 2025-11-06 | -$81.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$22.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$32.60M 10-Q · filed 2025-08-07 | -$114.00M derived: sum of 3 quarters · filed 2026-02-26 | -$42.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$9.80M 10-Q · filed 2025-05-08 | -$91.20M derived: sum of 2 quarters · filed 2026-02-26 | -$19.20M derived: sum of 3 quarters · filed 2026-02-26 | $126.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$81.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$9.40M derived: sum of 2 quarters · filed 2026-02-26 | $136.40M derived: sum of 3 quarters · filed 2026-02-26 | -$78.60M 10-K · filed 2026-02-26 |
| 2023-09-30 | $72.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $217.80M derived: sum of 2 quarters · filed 2024-11-07 | $2.80M 10-Q · filed 2024-11-07 | $342.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $145.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$69.20M 10-Q · filed 2024-08-08 | $270.00M derived: sum of 3 quarters · filed 2025-02-27 | $28.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$215.00M 10-Q · filed 2024-05-09 | $124.20M derived: sum of 2 quarters · filed 2025-02-27 | -$117.00M derived: sum of 3 quarters · filed 2025-02-27 | -$90.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $339.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $98.00M derived: sum of 2 quarters · filed 2025-02-27 | $124.80M derived: sum of 3 quarters · filed 2025-02-27 | $240.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$241.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$214.40M derived: sum of 2 quarters · filed 2023-11-08 | -$98.90M 10-Q · filed 2023-11-08 | -$89.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $26.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $142.30M 10-Q · filed 2023-08-07 | $152.10M derived: sum of 3 quarters · filed 2024-02-28 | -$31.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $115.50M 10-Q · filed 2023-05-08 | $125.30M derived: sum of 2 quarters · filed 2024-02-28 | -$58.50M derived: sum of 3 quarters · filed 2024-02-28 | -$3.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$174.00M derived: sum of 2 quarters · filed 2024-02-28 | -$119.10M derived: sum of 3 quarters · filed 2024-02-28 | -$59.30M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$183.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$128.90M derived: sum of 2 quarters · filed 2022-11-07 | -$69.10M 10-Q · filed 2022-11-07 | -$175.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $54.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $114.70M 10-Q · filed 2022-08-08 | $8.70M derived: sum of 3 quarters · filed 2023-02-27 | $158.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $59.80M 10-Q · filed 2022-05-09 | -$46.20M derived: sum of 2 quarters · filed 2023-02-27 | $103.70M derived: sum of 3 quarters · filed 2023-02-27 | $54.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$106.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $43.90M derived: sum of 2 quarters · filed 2023-02-27 | -$5.10M derived: sum of 3 quarters · filed 2023-02-27 | -$78.70M 10-K · filed 2023-02-27 |
| 2020-09-30 | $149.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $100.90M derived: sum of 2 quarters · filed 2021-11-08 | $27.30M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$122.60M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$73.60M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $20.00M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$340.10M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |